World – Iran
Chairman of the Board of Directors of the company Obaidi Amir Radwanian said in August 2016 that Gloriba had opened before the Minister of Health, Qazi Zadeh Hashmi, and is now available in pharmacies throughout the country. The company produced the drug shortly after the introduction of ampagliphosin in Europe and the United States, and in particular in the treatment of diabetes, especially Dr. It is hoped that Obaidi will gain the trust of doctors and patients in the quality of their pharmaceutical products.
Adel Jahid, a specialist in endocrinology and metabolism, says diabetes is not only a disorder of insulin secretion, but also dysfunction of other organs in the body, such as impaired glucose intake in the kidneys and urinary tract, to increase blood glucose levels, it helps.
Ampagliphlosine belongs to the new drug class (SGLT2) (Sodium Glucose Co-Transporter 2), the mechanism of action of anti-diabetic drugs present in the Iranian market is quite different. significant. People with diabetes are 2 to 4 times more likely to have cardiovascular disease than others. Although there are many anti-diabetic drugs in the world market, cardiovascular disease constitutes more than half of all cases. Mortality rates for these people.
According to Babek Şerif Kashani, a cardiologist and chairman of the World Cardiac Disorders Association, he has the ability to reduce the mortality rate by 38 percent in patients with diabetes and cardiovascular problems, unlike other oral therapies between this drug and diabetes. The hospitalization rate for heart failure was 35% in diabetic patients.